3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
16
Carcinoma, Renal Cell
14
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
7
Carcinoma, Hepatocellular
7
Neoplasms
6
Carcinoma, Medullary
6
Thyroid Neoplasms
5
Melanoma
5
Breast Neoplasms
5
Ovarian Neoplasms
4
Neuroendocrine Tumors
4
Carcinoma, Transitional Cell
4
Brain Neoplasms
4
Thyroid Cancer, Papillary
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Kidney Neoplasms
3
Adenocarcinoma, Follicular
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Recurrence
2
Pheochromocytoma
2
Paraganglioma
2
Pain
2
Osteosarcoma
2
Multiple Myeloma
2
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
12
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Axitinib
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Erlotinib Hydrochloride
5
Docetaxel
5
Cyclophosphamide
5
Albumin-Bound Paclitaxel
5
Sorafenib
4
Radiation
4
Nivolumab
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Irinotecan
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
pralsetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
cabozantinib
×
Clear all
NCT03755791
2025-12-11
COSMIC-312
Exelixis
Phase 3
Active not recruiting
837 enrolled
14 charts
NCT03937219
2025-09-10
COSMIC-313
Exelixis
Phase 3
Active not recruiting
855 enrolled
12 charts